Children's Mercy Kansas City

SHARE @ Children's Mercy

Research Days

GME Research Days 2023

May 11th, 12:15 PM - 12:30 PM

Cardiac Biomarkers Differentiate Kawasaki Disease from Multisystem Inflammatory Syndrome in Children Associated with COVID-19

Mollie Walton Children's Mercy Kansas City

Let us know how access to this publication benefits you

Follow this and additional works at: https://scholarlyexchange.childrensmercy.org/researchdays



🍑 Part of the Cardiology Commons, Medical Biochemistry Commons, and the Pediatrics Commons

Walton, Mollie, "Cardiac Biomarkers Differentiate Kawasaki Disease from Multisystem Inflammatory Syndrome in Children Associated with COVID-19" (2023). Research Days. 9. https://scholarlyexchange.childrensmercy.org/researchdays/GME_Research_Days_2023/ResearchDay4/9

This Oral Presentation is brought to you for free and open access by the Conferences and Events at SHARE @ Children's Mercy. It has been accepted for inclusion in Research Days by an authorized administrator of SHARE @ Children's Mercy. For more information, please contact histeel@cmh.edu.

Cardiac Biomarkers Aid in Differentiation of Kawasaki Disease from Multisystem Inflammatory Syndrome Associated with COVID-19

Mollie Walton, MD on behalf of the International Kawasaki Disease Registry May 11, 2023













Background

Kawasaki Disease (KD)




Multisystem Inflammatory Syndrome Associated with COVID-19 (MIS-C)




Background

- Cardiac biomarkers are used in cardiac assessment
- Prior single-center & small reports have shown MIS-C patients have higher biomarker levels than KD

Amino-terminal prohormone natriuretic peptide (NTproBNP)



Cardiac troponin I (TnI)





Objectives

- Determine if cardiac biomarkers can differentiate KD versus MIS-C
- Assess biomarker relationship to clinical features



Methods: Inclusion criteria


- January 2020 July 2022
- 42 sites, 8 countries
- Contemporaneous **KD** and **MIS-C** patients



IKD Registry




Methods: Inclusion criteria



Methods: Data analysis

- Biomarkers highly skewed
 - Normalizing logarithmic transformation
- Multiple imputation of missing values
- Multivariable general linear regression models for associated factors
- Receiver operating curves used to determine biomarker cut points differentiating MIS-C vs KD


Results: Clinical presentation




Results: Clinical presentation

- MIS-C more likely to present with or require:
 - Shock
 - Renal dysfunction
 - Inotropic or respiratory support
 - ICU admission
 - Longer length of stay

Results: Biomarker distribution by diagnosis





Results: Clinical presentation and biomarkers

- Higher logNTproBNP was associated with:
 - Shock
 - ICU admission
 - Longer hospital stay
- Higher logTnI was associated with:
 - Shock
 - ICU admission



Results: Biomarkers and ventricular function


- Systolic function was lower for MIS-C
- Systolic function was associated with higher baseline logNTproBNP and logTnl



Results: Biomarkers and coronary artery


abnormalities


- Maximum coronary artery Z-score greater for KD
- Maximum coronary artery Z-score not associated with either biomarker






Results: Predictive characteristics of biomarkers for diagnosis







Results: Management

- KD and MIS-C similar intravenous immunoglobulin and antiplatelet therapy
- MIS-C received anticoagulation and steroids



Discussion

- NTproBNP is upregulated by myocardial stress
- Tnl is released during myocyte injury and inflammation
- Higher biomarkers with lower systolic function
 - Pressure, volume overload
 - Myocyte injury, inflammation
- Coronary artery abnormalities not solely associated with myocyte stress and/or inflammation



Limitations

- Registry-based study
- C-statistic
- NTproBNP as an acute phase reactant



Conclusions

- Large, diverse population of contemporaneous
 KD and MIS-C patients
- Higher NTproBNP and TnI levels predict MIS-C
 - Tnl ≥10 ng/L or NTproBNP ≥1500 ng/L
- Higher biomarker levels predict more severe clinical presentation and course
- Inclusion of biomarkers in evaluation of unclear cases

